Neuro Therapia is developing oral small molecule therapies that inhibit microglia cells to reduce neuroinflammation in central nervous system diseases. Their lead program, NTRX-07, has shown a favorable safety profile and potential cognitive improvement in Alzheimer’s disease patients during Phase 1b clinical trials.
Funding
$20.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CCFounders
Product
Problem
Central nervous system (CNS) diseases are often characterized by neuroinflammation, driven by the activation of microglia cells. Traditional drug development has focused on removing accumulated proteins, neglecting the therapeutic potential of targeting neuroinflammation directly. This leaves a gap in treatment options that address the inflammatory component of these diseases.
Solution
Neuro Therapia is developing oral, small molecule therapeutics designed to inhibit microglia cells and reduce neuroinflammation in the CNS. Their lead program, NTRX-07, aims to improve the brain's ability to form new connections, potentially leading to improved learning and memory. This approach offers a novel strategy for treating CNS conditions by targeting the inflammatory processes that contribute to disease progression. NTRX-07 has demonstrated a favorable safety profile and a pharmacokinetic profile consistent with preclinical studies.
Target Audience
The primary target audience includes individuals suffering from CNS diseases characterized by neuroinflammation, such as Alzheimer's disease, and the healthcare professionals who treat them.
Features
- Orally available small molecule formulation for convenient administration.
- Selective inhibition of microglia cells to modulate neuroinflammation.
- Potential to improve cognitive function by enhancing brain connectivity.
- Demonstrated favorable safety profile in Phase 1b clinical trials.
- Pharmacokinetic profile consistent with preclinical studies.